Goldman Sachs Raises BAX PT To $62

Goldman Sachs has issued a report raising the Baxter International Inc. BAX Price Target from $61 to $62.

According to the report, “We continue to believe that the market is overly pessimistic about the outlook for BAX (12.1X 2011E EPS vs. the Medical Supply group at 13.6X against projected 2011- 2014 EPS growth of 11.7% and 11.4%, respectively). 2011 should be a trough earnings year for Baxter with 2012 representing a positive inflection point back to low-double-digit EPS growth. We raise our 12-month price target on BAX to $62 (from $61), consistent with the increase in 2012E EPS.”

BAX closed at $51.05 yesterday.